Campagna leaving as CMO of Q32 Bio

Q32 Bio Inc. (NASDAQ:QTTB) said Adrien Sipos will step into the CMO role on an interim basis following the resignation of Jason Campagna. Sipos is president and CMO at advisory firm Praxico Inc.; she was head of immunology and late-stage clinical development at Biogen Inc. (NASDAQ:BIIB). Campagna, whose resignation is effective July 9, has been with Q32 since 2021 following stints at Intercept Pharmaceuticals Inc. and The Medicines Co.

Privately held Sling Therapeutics Inc. named Ken Lock chief commercial officer. The move comes as Sling prepares to start a Phase III trial of oral IGF1R inhibitor linsitinib for thyroid eye disease; Lock was chief commercial officer at Acelyrin Inc., which had prioritized development of anti-IGF1R antibody lonigutamab prior to its merger with Alumis Inc. (NASDAQ:ALMS). TPG launched Sling in 2022 with $35 million in funding...